J Freireich loved good science and a good fight

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

When I started my fellowship at MD Anderson Cancer Center in 1980, Dr. Freireich headed the Department of Developmental Therapeutics.

Freireich working with a blood cell separator centrifuge at
MD Anderson Hospital. Photo courtesy of MD Anderson Cancer Center

In the departmental clinical research meetings, the fellows were sitting in the back and observed Dr. Freireich leading the meeting expecting accurate presentation and criticizing the most senior faculty, if needed.

People argued loudly in disagreement, only to be friendly to each other once the meeting was over. I learned soon that for J Freireich, scientific accuracy and knowledge were more important than seniority.

He never let any one of us get away with sloppy, inaccurate presentation.

Over the years I have learned about his multiple scientific accomplishments that significantly impacted the life of cancer patients. I was duly impressed. However, I was much more impressed with his personality as a leader.

He was a man of principles, and he never caved to pressure from administrators. He was always willing to give up political capital if it required compromising his scientific principles.

He was perceived by some as a controversial figure, at times upholding controversial concepts. Nonetheless, he defended his views rationally and with conviction.

Dr. Freireich was among those who pioneered clinical research in oncology as a structured, scientifically-supported discipline. He was among those who developed the therapeutic principles of chemotherapy in cancer.

At the same time, he also understood the changes in the fields and the value of therapeutic disciplines, such as biologic therapies, targeted therapies, and immunotherapies. Even in his later years, he was quick to grasp new concepts, remaining a sharp observer and critic when appropriate.

I see myself among many others who are Dr. Freireich’s proud students, who feel blessed to have had the opportunity to have him as a mentor who had considerable impact on their careers and lives.


The author is a professor at the Department of Internal Medicine,
University of Michigan

Moshe Talpaz, MD
Professor, Department of Internal Medicine, University of Michigan
Table of Contents

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 
Moshe Talpaz, MD
Professor, Department of Internal Medicine, University of Michigan

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login